ACCELERATED HIGH-TECH RADIOTHERAPY DURING THE COVID-19

Oncologia i radiologia Kazakhstana Pub Date : 2023-03-31 DOI:10.52532/2521-6414-2023-1-67-10-13

Y. Ishkinin, R. Raimbekov, K. Datbayev, A. Goncharova, R. Akhunova, A. Omarova, S. Ossikbayeva, F. Khozhamkul, M. Omirzaq, O. Seitov, Z. Khudaibergenov, N. Omarbayeva

{"title":"ACCELERATED HIGH-TECH RADIOTHERAPY DURING \nTHE COVID-19","authors":"Y. Ishkinin, R. Raimbekov, K. Datbayev, A. Goncharova, R. Akhunova, A. Omarova, S. Ossikbayeva, F. Khozhamkul, M. Omirzaq, O. Seitov, Z. Khudaibergenov, N. Omarbayeva","doi":"10.52532/2521-6414-2023-1-67-10-13","DOIUrl":null,"url":null,"abstract":"Relevance: COVID-19 impacts the course of cancer depending on the status and volume of cancer patient vaccination against \nCOVID-19. \nThe study aimed to assess the impact of accelerated high-tech radiation therapy on the course of the oncological process, depending on the status and volume of COVID-19 vaccinations. \nMethods: This quantitative and qualitative prospective randomized controlled scientific study was conducted as part of the implementation of the scientific project, “Innovative approach to managing patients with cancer in the context of the COVID pandemic-19,” \nReg. No. AP13068657. The study involved 221 cancer patients. \nResults: COVID-19 was diagnosed in 54/221 (24.4%) of the study participants, 24 (22.4%) in the standard radiotherapy group, and \n30 (26.3%) in the experimental radiotherapy group. 49/221 (22.2%) of the participants were vaccinated. COVID-19 was detected in \none breast cancer patient in the experimental group (1.5%) two months after vaccination and two patients with prostate cancer (2.4%) \nfour months after vaccination. Relapse-free survival was registered in 59 (85.5%) breast cancer patients in the standard group and \n58 (85.3%) in the experimental group. The overall survival of breast cancer patients was 69 (100.0%) in the standard group and 68 \n(97.0%) in the experimental group. Relapse-free survival was registered in 32 (84.2%) prostate cancer patients in the standard group \nand 41 (89.1%) patients in the experimental group. The overall survival among prostate cancer patients was 34 (89.5%) in the standard \ngroup and 45 (97.8%) in the experimental group. The deaths were not related to COVID-19. The average treatment duration for breast \ncancer was less by 12.9 days, with prostate cancer– by 18.2 days. \nConclusion: In Kazakhstan, 4.8% of cancer patients with COVID-19 died in 2020-2021. The use of accelerated high-tech radiotherapy is justified in the context of the COVID-19 pandemic. Vaccination can prevent COVID-19 development in cancer patients","PeriodicalId":19480,"journal":{"name":"Oncologia i radiologia Kazakhstana","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncologia i radiologia Kazakhstana","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52532/2521-6414-2023-1-67-10-13","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Relevance: COVID-19 impacts the course of cancer depending on the status and volume of cancer patient vaccination against COVID-19. The study aimed to assess the impact of accelerated high-tech radiation therapy on the course of the oncological process, depending on the status and volume of COVID-19 vaccinations. Methods: This quantitative and qualitative prospective randomized controlled scientific study was conducted as part of the implementation of the scientific project, “Innovative approach to managing patients with cancer in the context of the COVID pandemic-19,” Reg. No. AP13068657. The study involved 221 cancer patients. Results: COVID-19 was diagnosed in 54/221 (24.4%) of the study participants, 24 (22.4%) in the standard radiotherapy group, and 30 (26.3%) in the experimental radiotherapy group. 49/221 (22.2%) of the participants were vaccinated. COVID-19 was detected in one breast cancer patient in the experimental group (1.5%) two months after vaccination and two patients with prostate cancer (2.4%) four months after vaccination. Relapse-free survival was registered in 59 (85.5%) breast cancer patients in the standard group and 58 (85.3%) in the experimental group. The overall survival of breast cancer patients was 69 (100.0%) in the standard group and 68 (97.0%) in the experimental group. Relapse-free survival was registered in 32 (84.2%) prostate cancer patients in the standard group and 41 (89.1%) patients in the experimental group. The overall survival among prostate cancer patients was 34 (89.5%) in the standard group and 45 (97.8%) in the experimental group. The deaths were not related to COVID-19. The average treatment duration for breast cancer was less by 12.9 days, with prostate cancer– by 18.2 days. Conclusion: In Kazakhstan, 4.8% of cancer patients with COVID-19 died in 2020-2021. The use of accelerated high-tech radiotherapy is justified in the context of the COVID-19 pandemic. Vaccination can prevent COVID-19 development in cancer patients

查看原文本刊更多论文

2019冠状病毒病期间加速高科技放疗

相关性:COVID-19对癌症病程的影响取决于癌症患者接种COVID-19疫苗的状况和数量。该研究旨在评估加速高科技放射治疗对肿瘤过程的影响，具体取决于COVID-19疫苗接种的状态和数量。方法:本定量和定性前瞻性随机对照科学研究是科学项目“COVID -19大流行背景下癌症患者管理的创新方法”的一部分，Reg。不。AP13068657。这项研究涉及221名癌症患者。结果:221例研究对象中有54例(24.4%)被诊断为COVID-19，标准放疗组24例(22.4%)，实验放疗组30例(26.3%)。49/221(22.2%)的参与者接种了疫苗。接种疫苗2个月后，实验组1例乳腺癌患者(1.5%)检出COVID-19，接种疫苗4个月后，实验组2例前列腺癌患者(2.4%)检出COVID-19。标准组59例(85.5%)乳腺癌患者无复发生存率，实验组58例(85.3%)。标准组乳腺癌患者总生存率为69例(100.0%)，实验组为68例(97.0%)。标准组32例(84.2%)前列腺癌患者无复发生存，实验组41例(89.1%)前列腺癌患者无复发生存。标准组前列腺癌患者总生存率为34例(89.5%)，试验组为45例(97.8%)。这些死亡与COVID-19无关。乳腺癌的平均治疗时间缩短了12.9天，前列腺癌的平均治疗时间缩短了18.2天。结论:在哈萨克斯坦，4.8%的COVID-19癌症患者在2020-2021年死亡。在COVID-19大流行的背景下，使用加速高科技放射治疗是合理的。接种疫苗可以预防癌症患者发生COVID-19

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncologia i radiologia Kazakhstana

自引率

0.00%

发文量